These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 19608765)

  • 1. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
    Lu X; Wang Q; Hu G; Van Poznak C; Fleisher M; Reiss M; Massagué J; Kang Y
    Genes Dev; 2009 Aug; 23(16):1882-94. PubMed ID: 19608765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metalloproteinases and osteoblast EGFR signaling in osteolytic bone metastasis of breast cancer.
    Lu X; Kang Y
    Cell Cycle; 2009 Dec; 8(23):3804-5. PubMed ID: 19934661
    [No Abstract]   [Full Text] [Related]  

  • 3. Interacting post-muscarinic receptor signaling pathways potentiate matrix metalloproteinase-1 expression and invasion of human colon cancer cells.
    Said AH; Hu S; Abutaleb A; Watkins T; Cheng K; Chahdi A; Kuppusamy P; Saxena N; Xie G; Raufman JP
    Biochem J; 2017 Feb; 474(5):647-665. PubMed ID: 28008134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases.
    Zhu J; Jia X; Xiao G; Kang Y; Partridge NC; Qin L
    J Biol Chem; 2007 Sep; 282(37):26656-26665. PubMed ID: 17636266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression.
    Park S; Jung HH; Park YH; Ahn JS; Im YH
    Biochem Biophys Res Commun; 2011 Apr; 407(4):680-6. PubMed ID: 21440529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad.
    Nickerson NK; Mohammad KS; Gilmore JL; Crismore E; Bruzzaniti A; Guise TA; Foley J
    PLoS One; 2012; 7(1):e30255. PubMed ID: 22276166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively.
    Liu YJ; Xu Y; Yu Q
    Oncogene; 2006 Apr; 25(17):2452-67. PubMed ID: 16314835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of tumor growth by antibody to ADAMTS1 in mouse xenografts of breast cancer.
    Hirano T; Hirose K; Sakurai K; Makishima M; Sasaki K; Amano S
    Anticancer Res; 2011 Nov; 31(11):3839-42. PubMed ID: 22110207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression.
    Hu F; Wang C; Guo S; Sun W; Mi D; Gao Y; Zhang J; Zhu T; Yang S
    Biochim Biophys Acta; 2011 Mar; 1809(3):200-10. PubMed ID: 21241837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent.
    Roztocil E; Nicholl SM; Davies MG
    Surgery; 2008 Aug; 144(2):245-51. PubMed ID: 18656632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
    Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
    Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
    Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
    Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
    Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
    Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
    Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
    Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
    Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
    Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.
    Wang F; Sloss C; Zhang X; Lee SW; Cusack JC
    Cancer Res; 2007 Sep; 67(18):8486-93. PubMed ID: 17875687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.
    Guo D; Huang J; Gong J
    Mol Cell Biochem; 2012 Apr; 363(1-2):179-90. PubMed ID: 22167620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases.
    Bu G; Lu W; Liu CC; Selander K; Yoneda T; Hall C; Keller ET; Li Y
    Int J Cancer; 2008 Sep; 123(5):1034-42. PubMed ID: 18546262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway.
    Taverna S; Pucci M; Giallombardo M; Di Bella MA; Santarpia M; Reclusa P; Gil-Bazo I; Rolfo C; Alessandro R
    Sci Rep; 2017 Jun; 7(1):3170. PubMed ID: 28600504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.